TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06030492
Drug: normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin is incised either midline or Pfannenstiel incision according to clinical situation , bladder dissection will be done , uterus will be incised by transverse lower segment incision , followed by delivery of the baby.~Uterine massage , ecbolics \& a trial for delivery of the placenta will be done.~Packing the placental bed with a towel soaked with normal Saline solution
Study: NCT02677636
Drug: MSRD-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSRD-100 is a topical gel.
Study: NCT02677636
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle is a topical gel without the active ingredients in MSRD-100
Study: NCT05136898
Drug: UGN-102
Approvals — FDA: no, EMA: no, PMDA: no
Description: UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid under chilled conditions, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.
Study: NCT04993729
Drug: T89 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: T89 capsule (trade name Dantonic®) is a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi.~T89 capsules, p.o. TID.
Study: NCT04993729
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules, p.o. TID.
Study: NCT05798481
Drug: Mixture of Sodium Nitrite and N-acetylcysteine (NAC) crytals.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exactly 2.5 mg or 5 mg sodium nitrite and 50 mg N-acetylcysteine are weighed and mixed together just before use. The mixture is placed under the participant's tongue. The powder slowly dissolves in saliva and generate S-nitrosoacetylcysteine. Investigators will ask the subjects not to swallow the drug at least for 30 min. Administration of nitrite and N-acetylcysteine individually at these concentrations is not expected to change any blood NO chemistry or the systemic blood pressure. Hence, investigators will not investigate the effects of nitrite and N-acetylcysteine individually in this study. Placebo control is not needed for this study because the baseline parameters will serve as control. Investigators will assess the drug effect based on the difference between pre-treatment and post-treatment values.
Study: NCT05341999
Drug: Ibuprofen 400 mg
Normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients will be prescribed ibuprofen medication as a single dose immediately after completion of root canal treatment.
Study: NCT00633230
Drug: standardized herbal formula, Sho-saiko-to (SST)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 capsules containing 700 mg of the Sho-saiko-to (SST) herbal extract/capsule and 28 mg of the excipients, magnesium stearate, and silicon dioxide/capsule 2 x day
Study: NCT05411861
Drug: Analgesic Non Narcotic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of protocol-specified volume of local analgesic
Study: NCT04104659
Drug: MK 6240
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET tracer, \[18F\]MK-6240 (an\[18F\]tau imaging agent,CerveauTechnologies)that has high affinity for the human phosphorylated tau deposits in AD brain offers new opportunities to investigate tau pathology.(Hostetler, Walji et al. 2016, Lohith, Bennacef et al. 2016, Walji, Hostetler et al. 2016, Lohith, Bennacef et al. 2017, Neelamegam, Yokell et al. 2017).We will evaluate this imaging agent in individuals from families with a known Autosomal Dominant Alzheimer's Disease (ADAD) mutation.~The planned dosage for \[18F\]MK-6240 is a single intravenous bolus injection of 185 MBq (5.0 mCi) in a large peripheral vein followed by a 10 mL normal saline (0.9% NaCl) flush.
Study: NCT05275946
Drug: Targeted alpha therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous administration
Study: NCT06351215
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar pill that is identical look-alike to study drug
Study: NCT02223416
Drug: RGB-10
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05891028
Drug: 68Ga-EB-ss-CPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 68Ga-EB-ss-CPT were intravenous injected into the patients before PET/CT scans
Study: NCT05891028
Drug: 64Cu-EB-ss-CPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 64Cu-EB-ss-CPT were intravenous injected into the patients before PET/CT scans
Study: NCT05868733
Drug: Day 1 Higher Dose (1×107 pfu)
Normalized name: herpesvirus 1, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: rVSV∆G-LASV-GPC
Study: NCT05868733
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06011798
Drug: foselutoclax
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental drug
Study: NCT04392921
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will undergo one of the two schedules or intravenous infusion, based on their ability to tolerate po intake in the post-operative period:~* All patients will receive 100mL of 5% dextrose administered intravenously initiated at the time of anesthesia induction at a rate of 0.73mg/min or 43.75mg/h and continued over 24 hours followed by:~  o If able to tolerate po intake: 400mg po BID for post-operative days 1 to 5 or until the day of discharge (whichever occurs first).~* Esophagectomy patient will receive 100mL of 5% dextrose at the time of anesthesia induction at a rate of what would be 0.73mg/min or 43.75mg/h if it contained 1050mg of amiodarone, followed by daily infusion of 100mL of 5% dextrose for 4 days or until the day of discharge (whichever occurs first).
Study: NCT05124457
Drug: Insulin NPH
Normalized name: insulin NPH human isophane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are to receive insulin NPH
Study: NCT05039658
Drug: IBI110
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI110 is a high-affinity, ligand-blocking, humanized anti- Lymphocyte Activation Gene-3 (LAG-3) IgG4 antibody that blocks the binding of LAG-3 to MHCII.
Study: NCT05476432
Drug: FOLFOX 2d
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin, leucovorin, bolus fluorouracil, and infusional fluorouracil 2400 mg/m² over 46 hours
Study: NCT04656106
Drug: Ryzodeg®
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients have been treated at the discretion of the treating physician in accordance with the Ryzodeg® label in South Korea. Hence independently of this study, the treating physician has determined the starting dose of Ryzodeg® as well as any dose adjustments thereafter.
Study: NCT05680155
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Injection with matched volume
Study: NCT04186247
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weeks 4-12: 7.5 mg/kg azithromycin once daily (500 mg/day maximum) for five consecutive days/ week for 4 weeks, and 3 times a week for the following 4 weeks
Study: NCT06282965
Drug: Sterile saline
Normalized name: Aqua Care Sterile Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile solution of 0.9% NaCl in water.
Study: NCT04791059
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sufentanil 4 microgram/kg (maximum 250 microgram) is included in the mixture for patient-controlled analgesia.
Study: NCT05823844
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo pill will look identical to Suvorexant and will be taken as 2 tablets.
Study: NCT05007977
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single SC injection of placebo during hypoglycemic clamp
Study: NCT05720364
Drug: TP-05 (lotilaner oral), fasted group
Approvals — FDA: no, EMA: no, PMDA: no
Description: TP-05 (lotilaner oral), fasted group
Study: NCT05720364
Drug: TP-05 (lotilaner oral), high-fat group
Approvals — FDA: no, EMA: no, PMDA: no
Description: TP-05 (lotilaner oral), high-fat group
Study: NCT05720364
Drug: TP-05 (lotilaner oral), low-fat group
Approvals — FDA: no, EMA: no, PMDA: no
Description: TP-05 (lotilaner oral), low-fat group
Study: NCT04626089
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to placebo will take a tablet bid (PO) plus standard treatment for 14 days
Study: NCT06049810
Drug: IBI112
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive Dose 1 IBI112 through week 8 \& Dose 2 IBI112 on week 20 \& Dose 1 IBI112 through week 44
Study: NCT06049810
Drug: IBI112/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive Dose 1 IBI112 through week 8 \& Dose 2 IBI112 on week 20 \& placebo through week 44 by subcutaneous injection
Study: NCT05300841
Drug: estradiol valerate 2 mg /d (white tablets of cycloprognova, Bayer Shering, Germany)
Approvals — FDA: no, EMA: no, PMDA: no
Description: will receive dydrogestrone 10mg /day plus estradiol valerate 2 mg /d (white tablets of cycloprognova, Bayer Schering, Germany) for 10 days.
Study: NCT06049810
Drug: IBI112/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive Dose 1 IBI112 through week 8 \& Dose 3 IBI112 on week 20 \& placebo through week 44
Study: NCT06049810
Drug: IBI112
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive Dose 1 IBI112 through week 8 \& Dose 3 IBI112 on week 20 \& Dose 1 IBI112 through week 44
Study: NCT06049810
Drug: IBI112
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive Dose 1 IBI112 through week 8 \& Dose 3 IBI112 through week 44
Study: NCT06049810
Drug: IBI112
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive Dose 1 IBI112 through week 8 \& Dose 2 IBI112 through week 44 by subcutaneous injection
Study: NCT06250062
Drug: Recombinant humanized IL-17A Monoclonal Antibody（JS005）
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection
Study: NCT06250062
Drug: Placebo（JS005）
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection
Study: NCT04095689
Drug: IL-12 gene therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenoviral-mediated IL-12
Study: NCT01309022
Drug: Mycophenolic acid
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
Study: NCT04749394
Drug: Apatinib, VEGFR2 antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib 250mg PO, QD, until clinical progression/deterioration or confirmed radiological progression, or up to 1 year.
Study: NCT06508372
Drug: topical placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: In each patient a single similar psoriatic plaque on the other side of the body \[as regard anatomical site, size and TES (thickness, erythema, scales) score\] will be treated with placebo ointment twice daily for 3 months as a control.
Study: NCT04866355
Drug: Hyoscine and Ibuprofen
Normalized name: hydrocodone and ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: hyoscine (20 mg) and ibuprofen (400 mg) administered by oral via.
Study: NCT06429579
Drug: Only conventional drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only conventional drug therapy (i.e., Prostacyclin analogues, PDE-5 inhibitors, and Endothelin receptor antagonists)
Study: NCT04809974
Drug: Niagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention consists of taking Niagen and completing all tasks divided into 6 visits.
Study: NCT03191370
Drug: Local Anesthetics,Topical
Normalized name: LOCAL ANESTHETICS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthetic spray
Study: NCT05759468
Drug: Investigational Product - MIB 626
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: The eligible participants will be assigned to receive either NMN or placebo using concealed block randomization in a 1:1 ratio, stratified by sex (male, female), age (60 to 75, \>75 years) and trial site. The randomization list will be generated by the unblinded biostatistician using the software R (www.r-project.org), and deployed in a secure, centralized web-based application accessible to study staff following confirmation of a participant's eligibility.
Study: NCT05759468
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - Participants randomized to placebo will receive Matching placebo tablets will be provided by Metro International Biotech, LLC.
Study: NCT05669586
Drug: Antitumor therapy guided by organoid drug sensitivity test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antitumor therapy guided by organoid will be given to Multi-line Drug-resistant Non-small Cell Lung Cancer patients.
Study: NCT05202821
Drug: PRG Barrier Coat
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 arm randomized single blind clinical trial comparing 3 groups. first group will be receiving fluoride varnish, second group will be receiving PRG Barrier Coat and the third group will be receiving MI paste
Study: NCT05202821
Drug: MI paste
Normalized name: MI Paste One Fresh Mint Toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third group will be receiving MI paste
Study: NCT05045170
Drug: Influence of spinal anesthesia on memory consolidation and 'working memory'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia is performed by anesthesiologist. Memory testing is conducted immediately prior to operation (stage 1), 5-10 minutes after the start of operation (stage 2), 10 minutes before the end of operation (stage 3). Five emotionally neutral words are heard by the patients twice at each stage to assess the impact of sedation on memory consolidation. The patients repeat the memorized words after each audition. To assess the effect of sedation on the 'working memory', anesthesiologist asked the patient to remember and reproduce the memorized words five minutes after learning in the second stage. Approximately, 24 hours after the end of anesthesia, recall and recognition of the experimental words are tested. The number of words in recall and recognition testing is recorded by researcher.
Study: NCT06135363
Drug: SC1011
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC1011 tablet
Study: NCT06135363
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC1011-matching placebo tablet
Study: NCT04576078
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of a placebo 2 hours before the surgery following by one administration each 8h for 24h. Oral placebo is prepared ex-tempore with a taste masking compound by a non-charge nurse following detailed instructions
Study: NCT04988997
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBO - weekly SC administration
Study: NCT06358586
Drug: Tachipirina® 120 mg/5 mL oral suspension, new flavour
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of the Tachipirina® 120 mg/5 mL oral suspension(10 mL) will be administered to healthy paediatric volunteers under fasting conditions for at least 1 h before IMP administration until completion of palatability assessment.
Study: NCT04216927
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gNO will be entrained at 20 ppm into the oxygenator of the CPB circuit
Study: NCT05801055
Drug: Evaluation of gastric visibility following the combination drink of N-acetyle cysteine and simethocone
Approvals — FDA: no, EMA: no, PMDA: no
Description: The combination drink containing N-acetyl cysteine and simethicone help to disperse bubbles and mucus present in the stomach. During routine upper gastrointestinal endoscopy mucus and bubbles sometimes may hinder mucosal visibility, so small submucosal lesions, ulcers, erosions, and even flat pre-malignant lesions can be missed during endoscopy. The Japanese guidelines also recommend the use of this combination drink to detect early gastric cancers. So we plan to evaluate the role of this drink in improving gastric mucosal visibility in patients undergoing upper gastrointestinal endoscopy.
Study: NCT05737277
Drug: Gabapral
Approvals — FDA: no, EMA: no, PMDA: no
Description: This will be a randomised, double-blind, placebo-controlled, parallel-arm trial, designed to evaluate the efficacy and safety of Bifidobacterium adolescentis PRL2019 in pediatric patients (\> 4 years) with IBS (as assessed according to the Rome IV diagnostic criteria for IBS).~The study will include a 2-week screening period, and a 12-week placebo-controlled treatment period (Figure 1). After the screening phase, eligible patients will be randomly assigned to either 1 stick containing 20 Mld UFC of Bifidobacterium adolescentis PRL2019 (Gabapral, Pontenure, Italy), or the equivalent placebo once a day, in a 1:1 ratio, for 12 weeks. Study visits will be conducted every 4 weeks during the treatment period.
Study: NCT05737277
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This will be a randomised, double-blind, placebo-controlled, parallel-arm trial, designed to evaluate the efficacy and safety of Bifidobacterium adolescentis PRL2019 in pediatric patients (\> 4 years) with IBS (as assessed according to the Rome IV diagnostic criteria for IBS).~The study will include a 2-week screening period, and a 12-week placebo-controlled treatment period (Figure 1). After the screening phase, eligible patients will be randomly assigned to either 1 stick containing 20 Mld UFC of Bifidobacterium adolescentis PRL2019 (Gabapral, Pontenure, Italy), or the equivalent placebo once a day, in a 1:1 ratio, for 12 weeks. Study visits will be conducted every 4 weeks during the treatment period
Study: NCT05429073
Drug: RGLS8429
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution for subcutaneous injection
Study: NCT05429073
Drug: Placebo volume-matching RGLS8429 dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution for subcutaneous injection
Study: NCT06397508
Drug: AGMB-129
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each participant will receive 3 study interventions, 1 in each intervention period
Study: NCT03859921
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with appearance similar to Dydrogesterone
Study: NCT05644093
Drug: SPL026 IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV dosing
Study: NCT05644093
Drug: SPL026 IM
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM dosing
Study: NCT05464745
Drug: PERINDOPRES® DUO 8 mg perindopril tert-butylamine / 2.5 mg indapamide tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, generic fixed-dose combination of perindopril tert-butylamine (angiotensin-converting-enzyme inhibitor for the treatment of high blood pressure and heart failure) and indapamide (thiazide-like diuretic used in the treatment of hypertension and decompensated heart failure)
Study: NCT05464745
Drug: Noliterax® 10 mg/2.5 mg 10 mg perindopril arginine / 2.5 mg indapamide film-coated tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, innovative fixed-dose combination of perindopril arginine (angiotensin-converting-enzyme inhibitor for the treatment of high blood pressure and heart failure) and indapamide (thiazide-like diuretic used in the treatment of hypertension and decompensated heart failure)
Study: NCT04941404
Drug: TQ05105 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants began oral administration of TQ05105 tablets at 10 mg twice daily (BID),followed by 5 mg or 15 mg BID depending on the situation of the study. twice daily in 28-day cycle until disease progression/intolerance occurs or the sponsor terminates the study.
Study: NCT05818514
Drug: [11C]AZ14132516
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of radioligand for PET examinations
Study: NCT05607329
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemotherapy
Study: NCT06398925
Drug: OCT461201 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT06398925
Drug: OCT461201 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT06398925
Drug: OCT461201 150 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT06398925
Drug: OCT461201 450 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT06398925
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule
Study: NCT04558931
Drug: CellProtect
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro expanded and activated autologous NK cells
Study: NCT05549557
Drug: IMM40H
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMM40H is a monoclonal antibody with a molecular generated from ImmuneOnco's antibody platform. IMM40H targets CD70 (a tumor cell marker).
Study: NCT05054543
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Sodium Chloride
Study: NCT04831099
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The route of administration is transdermal.
Study: NCT04831099
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The route of administration is transdermal
Study: NCT05997576
Drug: TG103 22.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections with calorie restrict diet and increased physical activity for 52 weeks. Doses gradually increased from 7.5 mg to 22.5 mg.
Study: NCT05997576
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections with calorie restrict diet and increased physical activity for 52 weeks.
Study: NCT04825431
Drug: TAS-205, [14C]TAS-205
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral administration under fasted conditions on day 1
Study: NCT06280534
Drug: Test drug XT1061 capsules and placebo,Single dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eight people took capsules of the test drug XT1061 and two people took a placebo.
Study: NCT06280534
Drug: Test drug XT1061 capsules and placebo，Multiple dosing group
Approvals — FDA: no, EMA: no, PMDA: no
Description: D1-D7 were administered under fasting conditions for 7 consecutive days, of which D1-D6 were administered BID and D7 was administered once in the morning under fasting conditions only.Eight people took capsules of the test drug XT1061 and two people took a placebo.
Study: NCT06280534
Drug: Test drug XT1061 capsules and placebo，Food Impact Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eight people in group A took the test drug XT1061 capsules and two people took placebo, and all eight people in group B took the test drug XT1061 capsules.
Study: NCT05440136
Drug: Placebo (SC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT05440136
Drug: Placebo (IV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV.
Study: NCT05933980
Drug: Rego+Tori+Cele
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of Toripalimab,regorafenib and celecoxib